PHASE-II TRIAL OF TRIMELAMOL IN REFRACTORY OVARIAN-CANCER

被引：8
|
作者：
JUDSON, IR
CALVERT, AH
GORE, ME
BALMANNO, K
GUMBRELL, LA
PERREN, T
WILTSHAW, E
机构：
[1] INST CANC RES,MED SECT,SUTTON SM2 5PX,SURREY,ENGLAND
[2] ROYAL MARSDEN HOSP,LONDON,ENGLAND
来源：
BRITISH JOURNAL OF CANCER | 1991年 / 63卷 / 02期
基金：
英国医学研究理事会;
关键词：
D O I：
10.1038/bjc.1991.72
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Trimelamol is an analogue of hexamethymelamine which exhibited activity against refractory ovarian cancer in phase I clinical trial. The dose limiting toxicity was leukopenia. In a phase II study, 42 patients with recurrent, or platinum-complex resistant, advanced ovarian cancer were treated using the dose schedule 800 mg m-2 i.v. daily for 3 days. There were one complete, three partial and five minor responses, objective response rate: 9.5%. The main toxicity observed was nausea and vomiting, myelosuppression was minor. The role of Trimelamol in the treatment of ovarian cancer remains to be defined, but its activity is limited in refractory disease.
引用
收藏
页码：311 / 313
页数：3
相关论文
共 50 条
  • [1] PHASE-II TRIAL OF INTRAPERITONEAL MITOXANTRONE IN THE MANAGEMENT OF REFRACTORY OVARIAN-CANCER
    MARKMAN, M
    GEORGE, M
    HAKES, T
    REICHMAN, B
    HOSKINS, W
    RUBIN, S
    JONES, W
    ALMADRONES, L
    LEWIS, JL
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (01) : 146 - 150
  • [2] TENIPOSIDE IN REFRACTORY OVARIAN-CANCER - A PHASE-II STUDY
    SESSA, C
    DINCALCI, M
    LANDONI, F
    COLOMBO, N
    MANGIONI, C
    CANCER TREATMENT REPORTS, 1984, 68 (05): : 815 - 816
  • [3] A PHASE-II TRIAL OF 4-DEMETHOXYDAUNORUBICIN IN REFRACTORY EPITHELIAL OVARIAN-CANCER
    KAVANAGH, JJ
    COPELAND, LJ
    GERSHENSON, DM
    SAUL, PB
    EDWARDS, CL
    GYNECOLOGIC ONCOLOGY, 1986, 24 (01) : 23 - 26
  • [4] PHASE-II TRIAL OF DOCETAXEL IN PATIENTS WITH PLATINUM-REFRACTORY ADVANCED OVARIAN-CANCER
    FRANCIS, P
    SCHNEIDER, J
    HANN, L
    BALMACEDA, C
    BARAKAT, R
    PHILLIPS, M
    HAKES, T
    JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (11) : 2301 - 2308
  • [5] PACLITAXEL (TAXOL) TREATMENT FOR REFRACTORY OVARIAN-CANCER - PHASE-II CLINICAL-TRIAL
    SEEWALDT, VL
    GREER, BE
    CAIN, JM
    FIGGE, DC
    TAMIMI, HK
    BROWN, WS
    MILLER, SA
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1994, 170 (06) : 1666 - 1671
  • [6] CYCLIC HORMONAL TREATMENT IN OVARIAN-CANCER - A PHASE-II TRIAL
    JAKOBSEN, A
    BERTELSEN, K
    SELL, A
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (07): : 915 - 916
  • [7] PHASE-II TRIAL OF FLUDARABINE IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER
    KAVANAGH, JJ
    STRINGER, CA
    COPELAND, LJ
    GERSHENSON, DM
    SAUL, P
    CANCER TREATMENT REPORTS, 1986, 70 (03): : 425 - 426
  • [8] A PHASE-II TRIAL OF BISANTRENE (CL216,942) IN REFRACTORY EPITHELIAL OVARIAN-CANCER
    KAVANAGH, JJ
    GERSHENSON, DM
    SAUL, PB
    COPELAND, LJ
    GYNECOLOGIC ONCOLOGY, 1986, 23 (01) : 40 - 43
  • [9] PHASE-II TRIAL OF 5-FU ADMINISTERED IP TO PATIENTS WITH REFRACTORY OVARIAN-CANCER
    OZOLS, RF
    SPEYER, JL
    JENKINS, J
    MYERS, CE
    CANCER TREATMENT REPORTS, 1984, 68 (10): : 1229 - 1232
  • [10] PHASE-II STUDY OF PROLONGED ORAL ETOPOSIDE IN REFRACTORY OVARIAN-CANCER
    KAVANAGH, JJ
    TRESUKOSOL, D
    DELEON, CG
    EDWARDS, CL
    FREEDMAN, RS
    HORD, M
    HOWELL, E
    LENZI, R
    KRAKOFF, IH
    KUDELKA, AP
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1995, 5 (05) : 351 - 354
12345